Patents by Inventor Jean-Loup Romet-Lemonne

Jean-Loup Romet-Lemonne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040141998
    Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.
    Type: Application
    Filed: July 15, 2003
    Publication date: July 22, 2004
    Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
  • Patent number: 6713056
    Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: March 30, 2004
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
  • Publication number: 20040018184
    Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts:
    Type: Application
    Filed: July 21, 2003
    Publication date: January 29, 2004
    Applicant: I.D.M. IMMUNO-DESIGNED MOLECULES
    Inventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
  • Patent number: 6616925
    Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: September 9, 2003
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
  • Patent number: 6596275
    Abstract: Monocyte derived cells with immunosuppressive properties including an increase in at least one of the following PGE-2, IL-10 and IL-4. Monocyte derived cells with a decreased level of expression and secretion of inflammatory and immunostimulating cytokines and a decrease on the membrane of activation or accessory molecules in the presence of polylysine-cDNA in the nucleus of the monocyte derived cells.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: July 22, 2003
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Jacques Bartholeyns, Mohamed Chokri, Jean-Loup Romet-Lemonne
  • Publication number: 20020192193
    Abstract: The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CD40 and mannose receptor with a mean intensity of 50 to 500; they are substantially devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; and they have the property of stimulating the proliferation of allogenic lymphocytes.
    Type: Application
    Filed: July 15, 2002
    Publication date: December 19, 2002
    Applicant: I.D.M. IMMUNO-DESIGNED
    Inventors: Mohamed Chokri, Jacques Bartholeyns, Jean-Loup Romet-Lemonne
  • Publication number: 20020192192
    Abstract: The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CD40 and mannose receptor with a mean intensity of 50 to 500; they are substantially devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; and they have the property of stimulating the proliferation of allogenic lymphocytes.
    Type: Application
    Filed: July 15, 2002
    Publication date: December 19, 2002
    Applicant: I.D.M. IMMUNO-DESIGNED
    Inventors: Mohamed Chokri, Jacques Bartholeyns, Jean-Loup Romet-Lemonne
  • Publication number: 20020182725
    Abstract: The invention relates to monocytes derived antigen presenting cells (MDAPCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen (CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CI)40 and mannose receptor with a mean intensity of 50 to 500; they are substantiallv devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; they have the property of stimulating the proliferation of allogenic lymphocytes.
    Type: Application
    Filed: November 23, 1998
    Publication date: December 5, 2002
    Inventors: MOHAMED CHOKRI, JACQUES BARTHOLEYNS, JEAN-LOUP ROMET-LEMONNE
  • Publication number: 20010048922
    Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.
    Type: Application
    Filed: July 3, 2001
    Publication date: December 6, 2001
    Applicant: Medarex, Inc.
    Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
  • Patent number: 6258358
    Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 10, 2001
    Assignee: Medarex, Inc.
    Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
  • Patent number: 6248332
    Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: June 19, 2001
    Assignee: Medarex, Inc.
    Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
  • Patent number: 6221576
    Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from-monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits of reducing this process to practice.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: April 24, 2001
    Assignee: I. D. M. Immuno-Designed Molecules
    Inventors: Jean-Loup Romet-Lemonne, Mohamed Chokri
  • Patent number: 6140122
    Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: October 31, 2000
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Jean-Loup Romet-Lemonne, Mohamed Chokri
  • Patent number: 5804442
    Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: September 8, 1998
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Jean-Loup Romet-Lemonne, Mohamed Chokri